Anagrelide Hcl

證據等級: L5

預測適應症: 0 個

Anagrelide HCL: Evaluation Incomplete — No TxGNN Prediction Generated

One-Sentence Summary

Anagrelide HCL (INN: anagrelide) is a phosphodiesterase 3 inhibitor used in the management of essential thrombocythaemia, a chronic myeloproliferative disorder characterised by excess platelet production. The TxGNN model did not generate any repurposing predictions for this compound in the current data run, and no UK marketing authorisation data was retrieved. A full repurposing evaluation cannot proceed until the data gaps identified below are resolved.

Quick Overview

Item	Content
Original Indication	Essential thrombocythaemia (based on known clinical use; not retrieved in this data run)
Predicted New Indication	No prediction generated
TxGNN Prediction Score	Not available
Evidence Level	Not assessable
UK Market Status	Not found in current dataset (0 authorisations retrieved)
Number of Marketing Authorisations	0 (as retrieved)
Recommended Decision	Hold

Why Is No Prediction Available?

Anagrelide is a well-characterised medicine with a clear mechanism of action: it inhibits phosphodiesterase 3 (PDE3), which in turn reduces megakaryocyte maturation and lowers platelet counts. Its established pharmacology makes it a plausible candidate for investigation in other myeloproliferative conditions. However, the TxGNN knowledge graph requires drug entries to be matched via a standardised INN or DrugBank identifier — and in this pipeline run, no DrugBank ID was linked to this compound.

The most likely cause of the missing prediction is a drug name mismatch. The compound was queried as ANAGRELIDE HCL (the salt form), which may not align with the INN anagrelide as indexed in the TxGNN knowledge graph. A similar mismatch would explain why the MHRA marketing authorisation search returned zero results: anagrelide is in fact authorised and marketed in the UK under the brand name Xagrid (anagrelide hydrochloride 0.5 mg hard capsules).

The DrugBank query did return one successful result (result_count: 1), confirming the compound is identifiable — but the DrugBank ID was not propagated to the rest of the pipeline. Resolving this linkage issue is the critical first step before any repurposing evaluation can begin.

UK Market Information

No marketing authorisations were retrieved for ANAGRELIDE HCL in the current dataset.

Note for clinicians: Anagrelide is marketed in the United Kingdom as Xagrid with a valid MHRA marketing authorisation for essential thrombocythaemia. The absence of data in this evidence pack reflects a retrieval issue, not actual non-availability in the UK market. Please verify current authorisation status and prescribing information directly via the MHRA Product Licence database or the British National Formulary (BNF).

Safety Considerations

No safety data was retrieved in this evidence pack. Please refer to the Xagrid SmPC and the BNF for full prescribing information, including warnings regarding cardiovascular monitoring requirements. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model generated no repurposing predictions for this compound, and MHRA regulatory data was not retrieved — both failures stem from an unresolved drug name and identifier mismatch in the data pipeline. There is no evidence pack to evaluate at this stage.

To proceed, the following is needed:

Re-run the pipeline using the correct INN: anagrelide (not ANAGRELIDE HCL)
Resolve the DrugBank linkage: The query returned one result but did not populate a DrugBank ID; retrieve and propagate this identifier to unlock MOA data, DDI data, and TxGNN node matching
Re-retrieve MHRA data: Search under anagrelide or brand name Xagrid to obtain valid UK marketing authorisation records
Retrieve SmPC safety data: Including boxed warnings, contraindications, and drug interactions — this is currently rated as a blocking data gap (DG001)
Re-run TxGNN prediction: Once the correct drug node is identified in the knowledge graph, predictions and evidence collection (clinical trials, literature) can proceed normally

⚠️ Disclaimer: This report is generated for research purposes only and does not constitute medical advice. Any drug repurposing candidate requires clinical validation before therapeutic application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.